CTOs on the Move

Emisphere Technologies

www.emisphere.com

 
Emisphere Technologies, Inc. is a Cedar Knolls, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.emisphere.com
  • 240 Cedar Knolls Rd Ste 200
    Cedar Knolls, NJ USA 07927
  • Phone: 973.532.8000

Executives

Name Title Contact Details

Similar Companies

Inno Supps

Inno Supps is a natural supplement company based in Las Vegas that offers top tier products with clean, natural ingredients for athletes and individuals of all ages.

Shionogi USA Inc

Shionogi USA Inc is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EUSA Pharma

EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007. Our primary marketed products are

Critical Outcome Technologies

Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.